Bladder Cancer

Papers
(The median citation count of Bladder Cancer is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives10
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer9
Clinical Trials Corner Issue 8(1)8
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models8
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort8
Urologists and Advanced Practice Providers Evaluating Hematuria7
Antibiotics and BCG6
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer6
Clinical Trials Corner Issue 9(2)6
Standard vs extended lymphadenectomy for muscle invasive bladder cancer5
Comparison of Robotic vs Open Cystectomy: A Systematic Review4
CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract4
Organoid models in bladder cancer: From bench to bedside?4
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter4
Management of bladder cancer in kidney transplant recipients: A narrative review4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder4
Clinical Trials Corner Issue 10(2)4
A New Standard of Care for Bladder Cancer4
Clinical Trials Corner Issue 7(3)3
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors3
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer3
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes3
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review3
Challenging Cases in Urothelial Cancer: Case 262
Commentary on Novitas LCD2
Clinical Trials Corner Issue 8(2)2
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?2
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC2
Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab2
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma2
Y Chromosome Loss and Bladder Cancer2
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets2
Challenging Cases in Urothelial Cancer: Case 272
Challenging Cases in Urothelial Cancer: Case 332
Impact of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Population Based Analysis1
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer1
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”1
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States1
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates1
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics1
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review1
Open vs Robotic Surgery1
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors1
Clinical Trials Corner Issue 7(4)1
BCG in Immunocompromised Patients: Is it effective? Is it safe?1
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors1
Challenging Cases in Urothelial Cancer: Case 231
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma1
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer1
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy1
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease1
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol1
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells1
Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study0
A New Functional Gene, Zinc Finger Protein 485 (ZNF485), is Involved in Bladder Cancer Proliferation0
Qualitative Analysis of Pain in Patients With Locally Advanced or Metastatic Urothelial Carcinoma0
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer0
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis0
Challenging Cases in Urothelial Cancer: Case 290
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors0
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer0
Effect of Bacille Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer After Prostate Radiotherapy0
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E0
Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial0
Clinical Trials Corner Issue 10(1)0
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer0
Safety and Pharmacokinetics of Intravesical Chitosan/Interleukin-12 Immunotherapy in Murine Bladders0
Clinical Trials Corner Issue 9(1)0
Cost of Care in Open Cystectomy Patients Across Time and Space: Does it matter?0
The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence0
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 320
LncRNA HEIH/miR-4500/IGF2BP1/c-Myc Feedback Loop Accelerates Bladder Cancer Cell Growth and Stemness0
Combination of Two T1 Substaging Systems (T1a/b/c and T1m/e) Better Predicts Tumor Outcomes in Patients with T1 High Grade Bladder Cancer0
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer0
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer 0
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study0
The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands0
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study0
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer0
Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette–Guérin therapy in patients with non-muscle invasive bladder cancer0
Optimal Perioperative Chemotherapy for Muscle Invasive Bladder Cancer0
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer0
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer0
Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome0
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward0
Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life0
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer0
What is a Bladder Cancer Molecular Subtype?0
Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma0
A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma0
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen0
North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence0
Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer0
A Procedural Checklist for Transurethral Resection of Bladder Tumors (TURBT) Enhances Operative Dictation and Assesses Surgeon Accuracy of Tumor Characteristic Predictions0
Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study0
Quality of Life and Health State Utilities in Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 240
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays0
Repeat TURBT in large volume high-grade non-invasive bladder cancer0
Identification of a Novel Ferroptosis-Related Gene Signature for Prediction of Prognosis in Bladder Urothelial Carcinoma0
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis0
Clinical Trials Corner Issue 8(4)0
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile0
The Development of a Video-based Nutrition Education Curriculum for Patients Undergoing Radical Cystectomy0
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 220
Implementing a New Standard of Care0
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer0
Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively0
The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study10
Challenging Cases in Urothelial Cancer: Case 250
Clinical Trials Corner Issue 9(4)0
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy0
Salvage for BCG Unresponsive and Recurrent Disease0
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?0
The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC)0
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG0
Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model0
Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple?0
The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis0
What is a Bladder Cancer Molecular Subtype? – Counterpoint0
Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis0
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer0
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer0
Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration0
Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies0
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility0
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety0
Accuracy of Inchworm Sign on Diffusion-Weighted MRI in Differentiating Muscle-Invasive Bladder Cancer0
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis0
Clinical trials corner issue 11(1)0
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy0
0.044945001602173